PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $4.33.
A number of research firms have commented on PMVP. Weiss Ratings raised PMV Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, September 24th. Wall Street Zen downgraded PMV Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday, November 8th. Finally, HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of PMV Pharmaceuticals in a research report on Friday, September 4th.
Check Out Our Latest Stock Analysis on PMV Pharmaceuticals
Institutional Trading of PMV Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of PMVP. Goldman Sachs Group Inc. grew its position in shares of PMV Pharmaceuticals by 14.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 156,869 shares of the company's stock valued at $262,000 after buying an additional 19,875 shares during the last quarter. Empowered Funds LLC bought a new position in PMV Pharmaceuticals in the third quarter worth about $126,000. BML Capital Management LLC lifted its holdings in PMV Pharmaceuticals by 37.5% in the third quarter. BML Capital Management LLC now owns 7,330,000 shares of the company's stock worth $12,241,000 after acquiring an additional 2,000,000 shares during the last quarter. Cooper Haims Advisors LLC bought a new position in PMV Pharmaceuticals in the second quarter worth about $52,000. Finally, Susquehanna International Group LLP acquired a new position in PMV Pharmaceuticals in the second quarter valued at approximately $50,000. 90.20% of the stock is owned by institutional investors and hedge funds.
PMV Pharmaceuticals Stock Performance
Shares of NASDAQ:PMVP opened at $1.22 on Wednesday. The company has a market cap of $65.22 million, a P/E ratio of -0.79 and a beta of 1.52. PMV Pharmaceuticals has a one year low of $1.02 and a one year high of $1.91. The business's 50-day simple moving average is $1.38 and its 200 day simple moving average is $1.31.
PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.18). Analysts predict that PMV Pharmaceuticals will post -1.12 earnings per share for the current year.
About PMV Pharmaceuticals
(
Get Free Report)
PMV Pharmaceuticals is a biopharmaceutical company focused on developing precision cancer treatments. Its research centers on the tumor-suppressor protein p53, which is altered in many cancers, with the goal of restoring its function through targeted medicines. The company's lead investigational drug, rezatapopt (also known as PC14586), is designed to reactivate a specific mutated form of p53 called Y220C. PMV has studied the drug in clinical trials for patients with advanced solid tumors carrying that mutation.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider PMV Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PMV Pharmaceuticals wasn't on the list.
While PMV Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.